Drug Discovery World

MARCH 7, 2024

Delivery of synthesis targets within small molecule drug discovery often involves many chemists and other collaborators, both internal and external, across multiple locations. Join DDW and Cresset for this free event ‘ Enhancing collaboration in drug discovery – a biotech perspective ’.

Small Molecule 130

Small Molecule International Production Drugs 130

Drug Discovery World

FEBRUARY 29, 2024

Delivery of synthesis targets within small molecule drug discovery often involves many chemists and other collaborators, both internal and external, across multiple locations. Join DDW and Cresset for this free event ‘ Enhancing collaboration in drug discovery – a biotech perspective ’.

Small Molecule 130

Small Molecule Drugs International Production 130

Drug Discovery World

SEPTEMBER 29, 2022

Many companies have several projects ongoing simultaneously, which can limit internal resources (space, lab equipment, personnel) and delay progress. In asking these questions consider that internal resources may also have other commitments that delay progress. protein-protein or small molecule-target interactions).

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130

Drug Discovery World

FEBRUARY 13, 2024

AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. Systemic sclerosis is a chronic, progressive, autoimmune disease characterised by inflammation and fibrosis, such as uncontrolled scar tissue formation, in skin and various internal organs.

Disease 130

Disease Treatment Small Molecule Pharmacokinetics 130

DrugBank

MAY 15, 2024

One approach is to look beyond the traditional drug molecule. Researchers are experimenting with biologics—larger biological molecules that can do things small molecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

The Pharma Data

NOVEMBER 19, 2020

Program has advanced rapidly under an international collaboration of companies led by Sosei Heptares as part of its commitment to socially responsible investing. Sosei Heptares has successfully designed three distinct series of compounds with attractive anti-viral drug-like properties and advanced the most promising molecules.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Drug Discovery World

JUNE 1, 2023

AP-325 is a small molecule drug candidate that binds and modulates the GABAA receptor, reducing the excitability of the respective neurons. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France, and Italy.

Trials 130

Trials Small Molecule Drugs Pharmaceuticals 130

Covalent Modifiers

JANUARY 13, 2024

Thomas Kodadek Angewandte Chemie International Edition 2024 e202316726 [link] Many of the highest priority targets in a wide range of disease states are difficult-to-drug proteins.

Small Molecule 70

Small Molecule International Disease Drugs 70

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Mark Swallow , David Dible – International Media +44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D., GPCR – G protein-coupled receptors.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

OCTOBER 21, 2022

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .

Small Molecule 130

Small Molecule Virus Drugs Clinical Trials 130

Drug Target Review

JULY 6, 2023

1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. 1 The concept of TPD was first demonstrated with a heterobifunctional small molecule to degrader a protein of interest in the early 2000s.

Targeted Protein Degradation 98

Targeted Protein Degradation Small Molecule Clinical Trials Science 98

Drug Discovery World

FEBRUARY 22, 2023

More than 20% of new drugs are now coming from small innovative organisations and this percentage is increasing exponentially as these small organisations adopt this new technology. The supply chain design needs to be reviewed and difficult decisions about downsizing the internal supply footprint need to be made.

Small Molecule 130

Small Molecule Drug Development Drugs Packaging 130

Drug Discovery World

FEBRUARY 16, 2023

Dr Ouvry will be responsible for managing internal and external resources to advance the company’s pre-clinical pipeline of small molecule assets which inhibit the mitochondrial permeability transition pore (mPTP) through a novel MOA. Wang Zilong, H.E.L Group: H.E.L

Small Molecule 130

Small Molecule Pharmaceuticals Clinical Development Science 130

Drug Discovery World

DECEMBER 26, 2023

Anagenex and Nimbus Therapeutics Anagenex and Nimbus Therapeutics have initiated a research collaboration to discover small molecule drugs for multiple challenging targets. Peter Tummino, Nimbus’ Chief Scientific Officer, said: “At Nimbus, we have prioritised important but difficult-to-drug targets across multiple therapy areas.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

FEBRUARY 27, 2023

For RNA, we’ve seen its success with Covid-19 vaccines and the approval of the first-ever RNA-targeting small molecule, risdiplam, for treating spinal muscular atrophy (SMA). Do you have any therapeutic targets in mind for your first small molecule drug candidate? RT : Currently, we are developing our internal pipeline.

RNA 130

RNA Science Small Molecule Engineering 130

Dark Matter Blog

JANUARY 16, 2023

Our terra firma is small-molecule medicines. As we know, small molecules have been the mainstay of our pharmacopeia for several centuries and have, almost without exception, targeted proteins. This is why Arrakis set out in 2015 on an expedition to figure out how to develop small molecules that can target RNA.

Small Molecule 52

Small Molecule RNA International Disease 52

Covalent Modifiers

JULY 21, 2023

This allowed for tracking of PTK7 expression, localization, and cellular internalization. These studies validate the programmability of covalent aptamers and highlight their applicability in a cellular context, including protein and small molecule delivery

Small Molecule 52

Small Molecule International 52

Drug Discovery World

APRIL 6, 2023

from Fabien Vincent, Pfizer, Groton, US High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need by Neil Carragher, University of Edinburgh, Edinburgh, UK Functional genomics as an enabling tool for phenotypic screening by Matthew Garnett Chemistry to the Clinic: Part 1-3: (..)

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Target Review

JULY 13, 2023

They found that although the targets themselves may not be easily druggable due to their disordered nature, their ability to condense can be modulated using small molecules. By focusing on molecules that modulate the condensate formation, they identified tractable chemical matter that specifically impacted the target of interest.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

LifeSciVC

JULY 6, 2023

Although these results cannot prove that there is no possibility of finding a high-affinity small molecule binder of NBD1, they are discouraging…” It turns out the small molecules they were looking for are not only possible – they were ready for a dedicated team to push them ahead.

Small Molecule 48

Small Molecule Licensing Licensing Science 48

Drug Discovery World

APRIL 27, 2023

San Diego, California At the time of writing, the DDW team are in San Diego for SLAS2023 International Conference and Exhibition, which speaks to this Californian city’s appropriateness for such an integral event within the industry. We’re observing many stakeholders move to San Diego from other US hubs like Boston.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Discovery World

NOVEMBER 4, 2022

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. . References . Abanades et al. Bioinformatics 2021 .

Small Molecule 130

Small Molecule Bioinformatics Laboratories Engineering 130

LifeSciVC

JANUARY 16, 2024

The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

Drug Discovery World

APRIL 8, 2024

The company has participated in, and made possible, numerous AACR scientific meetings and think tanks where leaders from the national and international cancer research community have disseminated their novel findings. “On

DNA 130

DNA Small Molecule Science Treatment 130

Drug Target Review

NOVEMBER 6, 2023

These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. References Blood Cancer UK.

Small Molecule 110

Small Molecule Therapies Treatment Immune Response 110

LifeSciVC

APRIL 2, 2024

And the experience of those around you, including Board members and internal investors. We experienced strong enthusiasm for small molecule research in the investor community. The quality of science – and the ability to distinguish it from other approaches – was the entry ticket to serious engagement.

Science 67

Science Small Molecule International Clinical Development 67

The Strateos Blog: Drug Discovery

JULY 26, 2022

John summarized an internal case study highlighting the end-to-end idea-to-data capabilities of the automated platform to accelerate DMTA cycles. Fifteen structural analogs of the small molecule drug tofacitinib were successfully designed, synthesized, purified, and tested for functionality.

Small Molecule 52

Small Molecule International Production Drugs 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC and TTM Capital.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) International 40

Drug Discovery World

APRIL 10, 2023

The hub offers industrial/knowledge parks, special economic zones (SEZs), multi-tenanted dry and wet laboratories, and incubation facilities, attracting national and international companies. A second life sciences hub for the city is currently in development, expected to open in 2023.

Vaccine 130

Vaccine Pharmaceuticals Drugs Science 130

Drug Discovery World

JUNE 5, 2023

How best to communicate this strategy to both internal and external stakeholders? New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. How to improve its pipeline?

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

APRIL 25, 2023

In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors. Since its inception in 2018, BII has supported 80 start-ups and projects with €65 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level.

Science 130

Science Small Molecule Disease Government 130

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

Broad Institute

OCTOBER 17, 2023

Deik received her bachelor's degree in botany from Connecticut College and immediately went to work at International Paper, a paper manufacturing company, where she engineered trees to grow faster. At 11 years old, she knew she wanted to be a botanist. I run our lipid method, which annotates over 250 different lipids.

Research 98

Research Small Molecule Science Research Laboratories 98

DrugBaron

JANUARY 31, 2024

A simple example is called projection, where simple linear combinations of the data are used to extract the internal patterns within very large datasets – tools that were rightly called pattern recognition methods. And pattern recognition is not intelligence.

Pharma R&D 165

Pharma R&D Science Small Molecule Pharma Companies 165

The Premier Consulting Blog

JANUARY 31, 2023

Food and Drug Administration (FDA) adopted an addendum to the guidance titled “ S1B(R1) Testing for Carcinogenicity of Pharmaceuticals ,” which had previously been finalized by the International Council for Harmonization (ICH). 1,2,3 Its appendix offers case studies on the application of WoE in determining the utility of 2-year rat studies.

Small Molecule 52

Small Molecule Pharmaceuticals FDA Pharmacokinetics 52

New Drug Approvals

JANUARY 31, 2024

INAXAPLIN, 2446816-88-0 2446816-88-0 S2SJ2RVZ6Y UNII-S2SJ2RVZ6Y C 21 H 18 F 3 N 3 O 3 3-[5,7-difluoro-2-(4-fluorophenyl)-1 H -indol-3-yl]- N -[(3 S ,4 R )-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide Inaxaplin ( VX-147 ) is a small-molecule apolipoprotein L1 inhibitor developed by Vertex Pharmaceuticals for APOL1-mediated kidney disease.

International 52

International Disease Small Molecule Production 52